LCZ696

ApprovedSmall molecule

Novartis

LCZ696 is one of 175 small molecule programs targeting Mitral regurgitation. It is currently in Approved.

Indications

Total Trials

Active Trials

174

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

Essential HypertensionActive, not recruiting

Erectile DysfunctionActive, not recruiting

HypertensionActive, not recruiting

Heart FailureUnknown

Hypertrophic CardiomyopathyActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Mitral RegurgitationApproved

Active, not recruiting

Essential HypertensionPhase 2

Active, not recruiting

Erectile DysfunctionPhase 3

Active, not recruiting

HypertensionPhase 2

Active, not recruiting

Heart FailurePreclinical

Unknown

Hypertrophic CardiomyopathyPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

LCZ696

Novartis

Approved

15 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Zemplar

Savaysa

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 7

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure15 trials

Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction

Completed· Novartis logo

Novartis·Phase 3·NCT02468232·225 enrolled

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Terminated· Novartis logo

Novartis·Phase 3·NCT01035255·8,442 enrolled

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Completed· Novartis logo

Novartis·Phase 2/3·NCT02678312·393 enrolled

Show 12 more trials

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Completed· Novartis logo

Novartis·Phase 3·NCT01920711·4,822 enrolled

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Completed· Novartis logo

Novartis·Phase 3·NCT02884206·592 enrolled

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 2·NCT01353508·32 enrolled

Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

Completed· Novartis logo

Novartis·Phase 2·NCT01922089·498 enrolled

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Completed·—·Phase 4·NCT02816736·365 enrolled

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Completed· Novartis logo

Novartis·Phase 2·NCT00887588·307 enrolled

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Completed· Novartis logo

Novartis·Phase 4·NCT02690974·302 enrolled

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Completed· Novartis logo

Novartis·Phase 3·NCT02924727·5,669 enrolled

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

Completed· Novartis logo

Novartis·Phase 3·NCT02900378·621 enrolled

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Completed· Novartis logo

Novartis·Phase 4·NCT02768298·201 enrolled

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure

Completed· Novartis logo

Novartis·Phase 2·NCT00913653·30 enrolled

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

No longer available· Novartis logo

Novartis··NCT02389933

Essential Hypertension6 trials

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01785472·1,438 enrolled

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01615198·588 enrolled

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01193101·389 enrolled

Show 3 more trials

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01599104·1,161 enrolled

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT00549770·1,334 enrolled

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01256411·341 enrolled

Hypertension4 trials

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01692301·454 enrolled

Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01865188

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01281306·910 enrolled

Show 1 more trial

Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01681576·72 enrolled

Hypertensive3 trials

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Completed· Novartis logo

Novartis·Phase 3·NCT01593787·32 enrolled

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

Completed· Novartis logo

Novartis·Phase 2·NCT01631864·98 enrolled

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Completed· Novartis logo

Novartis·Phase 3·NCT01646671·35 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine

Completed· Novartis logo

Novartis·Phase 3·NCT01663233·266 enrolled

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Completed· Novartis logo

Novartis·Phase 3·NCT01876368·376 enrolled

13 more indications

Treatment1 trial

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Completed· Novartis logo

Novartis·Phase 3·NCT02226120·1,980 enrolled

Renal Impairment1 trial

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Completed· Novartis logo

Novartis·Phase 1·NCT01569815·32 enrolled

Patients With Advanced Solid Tumors1 trial

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

Completed·AAdvanced Accelerator Applications·Phase 1/2·NCT03872778·35 enrolled

Moderate Hepatic Impairment1 trial

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 2·NCT01621633·32 enrolled

Hypertrophic Cardiomyopathy1 trial

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Completed· Novartis logo

Novartis·Phase 2·NCT04164732·46 enrolled

ARB1 trial

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated·VVanderbilt University Medical Center·Phase 4·NCT03738878·4 enrolled

TED1 trial

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Terminated· Novartis logo

Novartis·Phase 3·NCT03909295·52 enrolled

Mild to Moderate Hypertension1 trial

Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01601470·28 enrolled

ALS1 trial

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Completed· Novartis logo

Novartis·Phase 4·NCT02874794·465 enrolled

Biomarkers1 trial

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

Completed· Novartis logo

Novartis·Phase 4·NCT02887183·794 enrolled

Mitral regurgitation1 trial

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation

Completed·—·Phase 4·NCT02687932·118 enrolled

Erectile Dysfunction1 trial

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

Completed· Novartis logo

Novartis·Phase 3·NCT03917459·27 enrolled

Acute1 trial

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

Completed· Novartis logo

Novartis·Phase 4·NCT02661217·1,002 enrolled

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for LCZ696. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LCZ696 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LCZ696. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

LCZ696

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure15 trials

Essential Hypertension6 trials

Hypertension4 trials

Hypertensive3 trials

Efficacy and Safety2 trials

Treatment1 trial

Renal Impairment1 trial

Patients With Advanced Solid Tumors1 trial

Moderate Hepatic Impairment1 trial

Hypertrophic Cardiomyopathy1 trial

ARB1 trial

TED1 trial

Mild to Moderate Hypertension1 trial

ALS1 trial

Biomarkers1 trial

Mitral regurgitation1 trial

Erectile Dysfunction1 trial

Acute1 trial

References

Drug Info

Quick Facts

Related News